These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9686647)

  • 1. HIV type 1 protease inhibitors fail to inhibit HTLV-I Gag processing in infected cells.
    Pettit SC; Sanchez R; Smith T; Wehbie R; Derse D; Swanstrom R
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):1007-14. PubMed ID: 9686647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells.
    Demir A; Oguariri RM; Magis A; Ostrov DA; Imamichi T; Dunn BM
    Antivir Ther; 2012; 17(5):883-92. PubMed ID: 22436331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 (HIV-1) Gag p7(NC) and the C-cleavage site impact Gag-Pol processing by HIV-1 protease.
    Goodenow MM; Bloom G; Rose SL; Pomeroy SM; O'Brien PO; Perez EE; Sleasman JW; Dunn BM
    Virology; 2002 Jan; 292(1):137-49. PubMed ID: 11878916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
    Tamiya S; Mardy S; Kavlick MF; Yoshimura K; Mistuya H
    J Virol; 2004 Nov; 78(21):12030-40. PubMed ID: 15479842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.
    Speck RR; Flexner C; Tian CJ; Yu XF
    Antimicrob Agents Chemother; 2000 May; 44(5):1397-403. PubMed ID: 10770790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of human immunodeficiency virus type 1 protease inhibitors against the initial autocleavage in Gag-Pol polyprotein processing.
    Davis DA; Soule EE; Davidoff KS; Daniels SI; Naiman NE; Yarchoan R
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3620-8. PubMed ID: 22508308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrates and inhibitors of human T-cell leukemia virus type I protease.
    Ding YS; Rich DH; Ikeda RA
    Biochemistry; 1998 Dec; 37(50):17514-8. PubMed ID: 9860866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of HTLV-I gag protease and its sequential processing of the gag gene product.
    Hatanaka M; Nam SH
    J Cell Biochem; 1989 May; 40(1):15-30. PubMed ID: 2663887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo processing of Pr160gag-pol from human immunodeficiency virus type 1 (HIV) in acutely infected, cultured human T-lymphocytes.
    Lindhofer H; von der Helm K; Nitschko H
    Virology; 1995 Dec; 214(2):624-7. PubMed ID: 8553565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.
    Mammano F; Petit C; Clavel F
    J Virol; 1998 Sep; 72(9):7632-7. PubMed ID: 9696866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative contribution of gag substitutions to nelfinavir-dependent enhancement of precursor cleavage and replication of human immunodeficiency virus type-1.
    Matsuoka-Aizawa S; Gatanaga H; Sato H; Koike K; Kimura S; Oka S
    Antiviral Res; 2006 Jun; 70(2):51-9. PubMed ID: 16487604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
    Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
    Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of human immunodeficiency virus type 1 protease increases intracellular cleavage of Gag and reduces virus infectivity.
    Luukkonen BG; Fenyö EM; Schwartz S
    Virology; 1995 Feb; 206(2):854-65. PubMed ID: 7856098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in the protease gene of human immunodeficiency virus type 1 affect release and stability of virus particles.
    Park J; Morrow CD
    Virology; 1993 Jun; 194(2):843-50. PubMed ID: 8503189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.
    Meek TD; Lambert DM; Dreyer GB; Carr TJ; Tomaszek TA; Moore ML; Strickler JE; Debouck C; Hyland LJ; Matthews TJ
    Nature; 1990 Jan; 343(6253):90-2. PubMed ID: 1688646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human T-cell leukemia virus type 1 protease protein expressed in Escherichia coli possesses aspartic proteinase activity.
    Saiga A; Tanaka T; Orita S; Sato A; Sato S; Hachisu T; Abe K; Kimura Y; Kondo Y; Fujiwara T
    Arch Virol; 1993; 128(3-4):195-210. PubMed ID: 8435041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.